IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Company/Organization Date Area of
Collaboration
Array BioPharma 2004 Diabetes and
hypertension
Terms of Agreement
The companies will utilize the US firm’s
technologies to develop improved
candidate drugs based on compounds
discovered by Takeda. The Japanese firm
will own the intellectual property
associated with the modified agents and
will pay Array compensation linked to the
latter’s contributions, as well as a fixed
percentage of sales for any drug that
enters the market.
Ligand Pharmaceuticals 2004 Drug development Under the terms of the agreement, Ligand
provided notice to TAP of its intention to
exercise its option to select within 90 days
one compound and a backup for
development. TAP retains an option to
negotiate to co-develop and co-promote
compounds with Ligand up to the end of
phase II. Ligand earned a $1 million
milestone payment from TAP as a result.
Ligand announced an extension of the
collaboration in December 2004 through
to June 2006.
University of Tokyo 2004 Drug
development/disease
prevention
Lectus Therapeutics 2004 Small-molecule ion
channels
Takeda joined a medical consortium
(including Tanabe, AnGes MG, and
Terumo) project which aims to provide a
base and incubation facilities for research
into new drugs, disease prevention, and
health-related services. Terms of the deal
were undisclosed at the time of writing.
Takeda Research Investment is funding
Lectus’ drug discovery and development
programs. Specific terms and conditions of
the deal were undisclosed at the time of
writing.
Innogenetics 2004 Alzheimer’s disease Innogenetics licensed patents rights to
Takeda’s beta-amyloid antibodies for
research and diagnostic use. Financial
terms of the deal were undisclosed at the
time of writing.
© 2009 IMS Health In cor po rated or its af fil i ates Page 102